

## **The Rare Disease Clinical Outcome Assessment Consortium: Aiming to Fulfill Unmet Drug Development Endpoint Measurement Needs**

Appropriate endpoint selection for rare disease trials is challenging. The Rare Disease Clinical Outcome Assessment (COA) Consortium's aim is the creation of a resource of publicly available COAs deemed fit-for-purpose as trial endpoint measures.

[You can view the full presentation here.](#)